INFI News and Press, Infinity Pharmaceuticals Inc. From 08/09/23

2023-08-09 06:00:00 ET 3 Tips for Trading Penny Stocks With a Full Time Job in 2023 Trading penny stocks has garnered significant attention in recent years, offering opportunities for investors seeking to diversify their portfolios and explore high-potential growth areas. Contrary to co...

2023-08-08 12:46:20 ET Gainers: Infinity Pharmaceuticals ( INFI ) +56% . Bright Minds Biosciences ( DRUG ) +46% . Tilray Brands ( TLRY ) +31% . Paymentus Holdings (PAY) +33% . Gorilla Technology Group ( GRRR ) +28% . Cardiff Onco...

2023-07-25 16:44:55 ET Infinity Pharmaceuticals ( NASDAQ: INFI ) said Tuesday it is reducing 78% of jobs across the company, which translates to about 21 positions, and trimming its board size to five from eight. The company expects to take a one-time charge of $3.4 million rela...

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced a series of actions design...

2023-07-24 08:50:08 ET Infinity Pharmaceuticals ( NASDAQ: INFI ) has terminated its previously announced merger agreement providing for the merger with MEI Pharma. At a special meeting of MEI stockholders on July 23, 2023, MEI did not obtain MEI stockholder approval for th...

Eganelisib Remains Primary Value Driver for Infinity Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a potential ...

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced that, based on a preliminary vote count, its stockholders have adopted...

2023-07-13 11:05:34 ET Summary Merger arbitrage spreads are wide. A number of opportunities with spreads from 9% to 135%. Below you'll find a review of the most interesting setups in the merger arbitrage space. Merger arbitrage is an event-driven investment strategy focu...

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced further design features of its Phase 2 MARIO-8 study in SCCHN. The...

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that leading independent proxy advisor Institutional S...